Aethlon Medical Amends Agreements, Allowing Immediate Exercisability of Pre-Funded Warrants
AEMD sits 36% above its 52-week low of $2.22.
Summary
Aethlon Medical amended its financing agreements, removing the shareholder approval requirement for pre-funded warrants, making them immediately exercisable and accelerating potential dilution.
Key Events · Financing and Capital Events · AEMD
-
Amendment to Securities Purchase Agreement
On January 22, 2026, Aethlon Medical and an institutional investor amended their Securities Purchase Agreement from December 5, 2025.
-
Amendment to Pre-Funded Common Stock Purchase Warrant
Concurrently, the company and the investor also amended the Pre-Funded Common Stock Purchase Warrant from December 8, 2025.
-
Removal of Shareholder Approval Requirement
Both amendments removed the condition requiring shareholder approval under Nasdaq 5635 for the pre-funded warrants to become exercisable.
-
Immediate Exercisability of Warrants
As a direct result of these amendments, the pre-funded warrants are now immediately exercisable, accelerating potential dilution for existing shareholders.
Analysis · AEMD · Industrial Applications And Services
Aethlon Medical has amended its Securities Purchase Agreement and Pre-Funded Common Stock Purchase Warrant, removing the requirement for shareholder approval (under Nasdaq 5635) for the pre-funded warrants to become exercisable. This change, effective January 22, 2026, means these warrants are now immediately exercisable, accelerating potential dilution. This follows recent filings, including a DEF 14A on January 16, 2026, which sought shareholder approval for proposals enabling over 200% dilution, and an S-1 registration on January 7, 2026, for the resale of over 2 million shares underlying various warrants. The removal of this shareholder safeguard for pre-funded warrants is a significant negative development, as it allows for immediate dilution without prior shareholder consent, intensifying the dilution risk for existing investors.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 362 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AEMD was trading at $3.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $2.22 to $64.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.